Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study

American Journal of Hospice and Palliative Medicine

Volumn 22, Issue 1, 2005, Pages 55-59

  Carter, Gregory T ^a   Weiss, Michael D ^a   Lou, Jau Shin ^b   Jensen, Mark P ^a   Abresch, R Ted ^c   Martin, Tara K ^a   Hecht, Thomas W ^a   Han, Jay J ^a   Weydt, Patrick ^a   Kraft, George H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyotrophic lateral sclerosis; Fatigue; Functional independence measure; Modafinil; Motor neuron disease

Indexed keywords

MODAFINIL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; FUNCTIONAL INDEPENDENCE MEASURE; HUMAN; INSOMNIA; MALE; NERVOUSNESS; PILOT STUDY; RATING SCALE; REVIEW; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 13444274616     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910502200112     Document Type: Review

References (48)

1. Miller RG, Rosenberg JA, Gelinas DF, et al.: Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review). Muscle Nerve. 1999; 22(8): 1104-1118.
2. Carter GT, Miller RG: Comprehensive management of amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 1998; 9(1): 271-284.
3. Carter GT, Krivickas LS: Adult motor neuron disease. In Kirshblum S, Campagnolo DL, DeLisa JA, (eds.): Spinal Cord Injury Medicine. Philadelphia: Lippincott, Williams, & Wilkins, 2002.
4. Lou JS, Reeves A, Benice T, et al.: Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003; 60(1): 122-123.
5. Norquist JM, Fitzpatrick R, Jenkinson C: Health-related quality of life in amyotrophic lateral sclerosis: Determining a meaningful deterioration. Qual Life Res. 2004; 13(8): 1409-1414.
6. Chio A, Gauthier A, Montuschi A, et al.: A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry. 2004; 75(11): 1597-1601.
7. Nelson ND, Trail M, Van JN, et al.: Quality of life in patients with amyotrophic lateral sclerosis: Perceptions, coping resources, and illness characteristics. J Palliat Med. 2003; 6(3): 417-424.
8. Ganzini L, Johnston WS, Hoffman WF: Correlates of suffering in amyotrophic lateral sclerosis. Neurology. 1999; 52(7): 1434-1440.
9. Miller RG: Role of fatigue in limiting physical activities in humans with neuromuscular diseases. Am J Phys Med Rehabil. 2002; 81(11): S99-107.
10. Sanjak M, Brinkmann J, Belden DS, et al.: Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis. J Neurol Sci. 2001; 191(1-2): 55-59.
11. Sanjak S, Konopcaki R, Capasso R, et al.: Dissociation between mechanical and myoelectrical manifestation of muscle fatigue in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(1): 26-32.
12. Kent-Braun JA, Miller RG: Central fatigue during isometric exercise in amyotrophic lateral sclerosis. Muscle Nerve. 2000; 23(6): 909-914.
13. Sharma KR, Kent-Braun JA, Majumdar S, et al.: Physiology of fatigue in amyotrophic lateral sclerosis. Neurology. 1995; 45(4): 733-740.
14. Sharma KR, Miller RG: Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis. Muscle Nerve. 1996; 19(11): 1391-1400.
15. Schiffman PL, Belsh JM: Effect of inspiratory resistance and theophylline on respiratory muscle strength in patients with amyotrophic lateral sclerosis. Am Rev Respir Dis. 1989; 139(6): 1418-1423.
16. Carter GT, Krivickas ES, Weydt P, et al.: Drug therapy for amyotrophic lateral sclerosis: Where are we now? IDrugs. 2003; 6(2): 147-153.
17. Weiss MD, Weydt P, Carter GT: Current pharmacological management of amyotrophic lateral sclerosis and a role for rational polypharmacy. Expert Opin Pharmacotherap. 2004; 5(4): 735-746.
18. Talbot K, Stradling J, Crosby J, et al.: Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord. 2003; 13(5): 357-364.
19. MacDonald JR, Hill JD, Tarnopolsky MA: Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology. 2002; 59(12): 1876-1880.
20. Damian MS, Gerlach A, Schmidt F, et al.: Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology. 2001; 56(6): 794-796.
21. Adler CH, Caviness JN, Hentz JG, et al.: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003; 18(3): 287-293.
22. Nieves AV, Lang AE: Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol. 2002; 25(2): 111-114.
23. Hogl B, Saletu M, Brandauer E, et al.: Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002; 25(8): 905-909.
24. Happe S, Pirker W, Sauter C, et al.: Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol. 2001; 248(7): 632-634.
25. Zifko UA, Rupp M, Schwarz S, et al.: Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol. 2002; 249(8): 983-987.
26. Rammohan KW, Rosenberg JH, Lynn DJ, et al.: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002; 72(2): 179-183.
27. Willoughby E: Modafinil for fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002; 72(2): 150.
28. Ferraro L, Antonelli T, O'Connor WT, et al.: The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport. 1997; 8(13): 2883-2887.
29. Ferraro L, Tanganelli S, O'Connor WT, et al.: The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett. 1996; 220(1): 5-8.
30. Touret M, Sallanon-Moulin M, Fages C, et al.: Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain. Brain Res Mol Brain Res. 1994; 26(1-2): 123-128.
31. Ueki A, Rosen L, Andbjer B, et al.: The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway. Exp Brain Res. 1993; 93(2): 259-270.
32. Antonelli T, Ferraro L, Hillion J, et al.: Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport. 1998; 9(18): 4209-4213.
33. Engber TM, Dennis SA, Jones BE, et al.: Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. Neuroscience. 1998; 87(4): 905-911.
34. Ferraro L, Antonelli T, Tanganelli S, et al.: The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABAA receptor blockade. Neuropsychopharmacology. 1999; 20(4): 346-356.
35. Lagarde D, Milhaud C: Electroencephalographic effects of modafinil, an alpha-1-adrenergic psychostimulant, on the sleep of rhesus monkeys. Sleep. 1990; 13(5): 441-448.
36. Duteil J, Rambert FA, Pessonnier J, et al.: Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; Studies with experimental animals. Eur J Pharmacol. 1990; 180(1): 49-58.
37. Mignot E, Nishino S, Guilleminault C, et al.: Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994; 17(5): 436-437.
38. Ishizuka T, Sakamoto Y, Sakurai T, et al.: Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003; 339(2): 143-146.
39. Ellis CM, Monk C, Simmons A, et al.: Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil. J Sleep Res. 1999; 8(2): 85-93.
40. Grey N, Kennedy P: The Functional Independence Measure: A comparative study of clinician and self ratings. Paraplegia. 1993; 31(7): 457-461.
41. Hoenig H, McIntyre L, Sloane R, et al.: The reliability of a self-report measure of disease, impairment, and function in persons with spinal cord injury. Arch Phys Med Rehabil. 1998; 79(4): 378-387.
42. Jensen MP, Abresch RT, Carter GT: The reliability and validity of a self-reported version of the functional independence measure in persons with neuromuscular disease and chronic pain. Arch Phys Med Rehabil 2004 (in press).
43. Schwartz JE, Jandorf L, Krupp LB: The measurement of fatigue: A new instrument. J Psychosom Res. 1993; 37(7): 753-762.
44. Johns MW: A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep. 1991; 14(6): 540-545.
45. Krupp LB, LaRocca NG, Muir-Nash J, et al.: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46(10): 1121-1123.
46. Elkins LE, Krupp LB, Scherl W: The measurement of fatigue and contributing neuropsychiatric factors. Semin Clin Neuropsychiatry. 2000; 5(1): 58-61.
47. Norris F, Sheperd R, Denys E, et al.: Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993; 118(1): 48-55.
48. Ringel SP, Murphy JR, Alderson MK, et al.: The natural history of amyotrophic lateral sclerosis. Neurology. 1993; 43(7): 1316-1322.